Chemomab Therapeutics Ltd.(CMMB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CMMB Chemomab Therapeutics Ltd.

交易中 09-14 13:37:33 EDT

2.47

-0.11

-4.26%

最高2.58	最低2.43	成交量5.03万
今开2.58	昨收2.58	日振幅5.81%
总市值1,810万	流通市值1,518万	总股本732.77万
成交额12.48万	换手率0.82%	流通股本614.41万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CMMB","market":"US","secType":"STK","nameCN":"Chemomab Therapeutics Ltd.","latestPrice":2.47,"timestamp":1789407442554,"preClose":2.58,"halted":0,"volume":50286,"delay":0,"changeRate":-0.04263565891472863,"floatShares":6144100,"shares":7327700,"eps":-1.006975,"marketStatus":"交易中","change":-0.11,"latestTime":"09-14 13:37:33 EDT","open":2.575,"high":2.5799,"low":2.43,"amount":124777.1761572,"amplitude":0.058101,"askPrice":2.48,"askSize":200,"bidPrice":2.43,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-1.006975,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":80,"listingDate":1549947600000,"exchange":"NASDAQ","adjPreClose":2.58,"preHourTrading":{"tag":"盘前","latestPrice":2.59,"preClose":2.58,"latestTime":"07:04 EDT","volume":351,"amount":921.5099945999999,"timestamp":1789383865832,"change":0.01,"changeRate":0.003876,"amplitude":0.042636},"postHourTrading":{"tag":"盘后","latestPrice":2.55,"preClose":2.58,"latestTime":"19:27 EDT","volume":914,"amount":2330.82,"timestamp":1789169270399,"change":-0.03,"changeRate":-0.011628,"amplitude":0.011628},"volumeRatio":0.949277},"requestUrl":"/m/hq/s/CMMB","defaultTab":"news","newsList":[{"id":"1110255402","title":"Chemomab Therapeutics Ltd：截至2026年6月30日，现金、现金等价物及短期银行存款达670万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110255402","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110255402?lang=zh_cn&edition=full","pubTime":"2026-08-19 20:30","pubTimestamp":1787142601,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd. 公布了截至2026年6月30日的财务状况。该公司持有的现金、现金等价物以及短期银行存款总额达到了670万美元。这一数据反映了公司在报告期内的流动性状况，显示出其资金储备的具体规模。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169927398","title":"Chemomab Therapeutics：Nebokitug类风湿关节炎2期临床试验预计2027年上半年启动，2028年上半年公布数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1169927398","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169927398?lang=zh_cn&edition=full","pubTime":"2026-08-19 20:29","pubTimestamp":1787142549,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd.近日宣布，其核心候选药物Nebokitug针对类风湿关节炎（RA）的2期临床试验预计将于2027年上半年正式启动。这项备受关注的研究有望在2028年上半年公布关键数据。\n这一时间表的确定，标志着公司在推进Nebokitug的临床开发进程中迈出了重要一步。作为一款备受期待的在研药物，Nebokitug的2期试验结果将为其后续的临床路径提供关键参考。市场对这款药物的研发进展保持着高度关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134858464","title":"Chemomab与Scipher合并后股权结构出炉：前者股东持股约32%，后者持股约68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134858464","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134858464?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:39","pubTimestamp":1783510754,"startTime":"0","endTime":"0","summary":"根据双方达成的合并协议，在交易完成后，Chemomab Therapeutics Ltd.的现有股东预计将持有合并后新公司约32%的股权。与此同时，Scipher Medicine的现有股权持有人预计将获得新公司约68%的股份。这一股权分配方案明确了合并后实体的控制权结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172693632","title":"Chemomab Therapeutics合并后将以Scipher Medicine Corporation运营，并在纳斯达克以股票代码“SCIP”交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1172693632","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172693632?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:37","pubTimestamp":1783510634,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics宣布，合并后的新实体将以Scipher Medicine Corporation的名义运营，其股票将在纳斯达克证券交易所挂牌交易，股票代码为“SCIP”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158326142","title":"Chemomab Therapeutics Ltd. 在顶级投资者3000万美元私募前，合并后公司估值达1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158326142","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158326142?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:37","pubTimestamp":1783510634,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd. (CMMB) 在获得顶级投资者3000万美元的私募融资前，其合并后公司的估值已高达1.5亿美元。这笔同步进行的私募配售进一步巩固了公司的资本实力，为后续发展提供了重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126455616","title":"Chemomab与Scipher Medicine达成合并协议，携手推进Nebokitug在AI驱动的类风湿关节炎二期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1126455616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126455616?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:36","pubTimestamp":1783510577,"startTime":"0","endTime":"0","summary":"精准医疗领域的先锋企业Scipher Medicine与生物技术公司Chemomab Therapeutics宣布，双方已就合并事宜达成最终协议。此次合并的核心目标，是加速推进Chemomab旗下在研药物Nebokitug的开发进程。该药物将在一项创新性的二期临床试验中进行评估，这项试验特别引入了人工智能技术，旨在针对类风湿关节炎患者群体探索更精准、高效的治疗方案。通过整合双方在生物标志物发现、人工智能分析及靶向疗法开发方面的专长，合并后的新实体期望能更有效地解锁Nebokitug的临床潜力，为类风湿关节炎患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173386437","title":"Chemomab与精准医疗先锋Scipher Medicine达成合并协议，将借助AI驱动推进Nebokitug治疗类风湿关节炎的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1173386437","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173386437?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:36","pubTimestamp":1783510575,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd. 与精准医疗领域的开拓者Scipher Medicine宣布达成合并协议。此次合作旨在加速其候选药物Nebokitug的开发进程，该药物将进入一项由人工智能技术支持的二期临床试验，以评估其对类风湿关节炎的治疗效果。这一战略举措旨在整合双方在生物技术与数据分析方面的专长，共同推进精准医疗在自身免疫性疾病领域的应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117558182","title":"Chemomab Therapeutics：评估Nebokitug产生强劲临床前疗效信号的更多适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1117558182","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117558182?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:10","pubTimestamp":1773922204,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd. 正在积极探索其核心候选药物Nebokitug的更多潜在治疗领域。目前，公司已基于该药物在临床前研究中展现出的强劲疗效信号，着手评估其应用于其他疾病适应症的可能性。这一举措旨在充分挖掘Nebokitug的治疗潜力，为未来拓展其临床应用范围奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518205270","title":"Chemomab Therapeutics Ltd盘中异动 股价大涨5.60%报1.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518205270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518205270?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:34","pubTimestamp":1741628065,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时34分，Chemomab Therapeutics Ltd股票出现异动，股价快速上涨5.60%。截至发稿，该股报1.32美元/股，成交量4.027万股，换手率0.21%，振幅7.20%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体涨幅为0.84%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311013426abf35526&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311013426abf35526&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518428095","title":"Chemomab Therapeutics Ltd2024财年实现净利润-14.01百万美元，同比增加42.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518428095","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518428095?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449676,"startTime":"0","endTime":"0","summary":"3月9日，Chemomab Therapeutics Ltd公布财报，公告显示公司2024财年净利润为-14.01百万美元，同比增加42.01%；其中营业收入为0.00美元，每股基本收益为-0.86美元。从资产负债表来看，Chemomab Therapeutics Ltd总负债3.43百万美元，其中短期债务114999.97美元，资产负债比为4.95，流动比率为4.99。机构评级：截至2025年3月9日，当前有3家机构对Chemomab Therapeutics Ltd目标价做出预测，其中目标均价为9.00美元，其中最低目标价为7.00美元，最高目标价为11.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000247abef9898&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000247abef9898&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517623381","title":"Chemomab Therapeutics Ltd盘中异动 早盘股价大涨6.43%报1.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517623381","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517623381?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:57","pubTimestamp":1741276670,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时57分，Chemomab Therapeutics Ltd股票出现波动，股价急速上涨6.43%。截至发稿，该股报1.49美元/股，成交量1.4753万股，换手率0.08%，振幅4.29%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体跌幅为0.58%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306235750989ec4fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306235750989ec4fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CMMB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517910044","title":"Chemomab Therapeutics Ltd盘中异动 早盘股价大涨9.47%报1.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517910044","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517910044?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185125,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分，Chemomab Therapeutics Ltd股票出现异动，股价快速上涨9.47%。截至发稿，该股报1.42美元/股，成交量1202股，换手率0.01%，振幅4.23%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体涨幅为0.20%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223205a260c786&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223205a260c786&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CMMB","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516166819","title":"Chemomab Therapeutics Ltd盘中异动 急速下挫5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516166819","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516166819?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:16","pubTimestamp":1741032963,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时16分，Chemomab Therapeutics Ltd股票出现波动，股价快速跳水5.35%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体涨幅为0.01%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041603989a5c4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041603989a5c4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CMMB","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188217444","title":"Chemomab Therapeutics第四季度每股收益$(0.008)与去年同期$(0.013)对比","url":"https://stock-news.laohu8.com/highlight/detail?id=1188217444","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188217444?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:12","pubTimestamp":1741007561,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics(LENZ)第四季度每股收益$(0.008)与去年同期$(0.013)对比。以上内容来自Benzinga Earnings专栏，原文如下：Chemomab $Therapeutics(LENZ)$ Q4 EPS $(0.008) vs $(0.013) YoY","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516301312","title":"Chemomab Therapeutics Ltd盘中异动 急速上涨5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301312","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516301312?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:58","pubTimestamp":1740776337,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时58分，Chemomab Therapeutics Ltd股票出现波动，股价急速上涨5.56%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体涨幅为0.69%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301045858a25856de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301045858a25856de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514096013","title":"Chemomab Therapeutics Ltd盘中异动 大幅下跌5.95%报1.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096013","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514096013?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:20","pubTimestamp":1740496823,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时20分，Chemomab Therapeutics Ltd股票出现波动，股价大幅下跌5.95%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体涨幅为0.83%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。CM-101已经显示出有潜力治疗多种严重和危及生命的纤维化和炎症性疾病。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225232023989257c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225232023989257c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296346","title":"Chemomab Therapeutics Ltd盘中异动 早盘股价大跌5.65%报1.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296346","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513296346?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148304,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Chemomab Therapeutics Ltd股票出现异动，股价快速跳水5.65%。截至发稿，该股报1.67美元/股，成交量2.9292万股，换手率0.16%，振幅2.26%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体涨幅为0.33%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223145988dde1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223145988dde1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512488052","title":"Chemomab Therapeutics Ltd盘中异动 早盘快速下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512488052","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512488052?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:32","pubTimestamp":1739975570,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时32分，Chemomab Therapeutics Ltd股票出现异动，股价大幅跳水5.02%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Osr Holdings Inc C/Wts 02/09/2028 、Aditxt, Inc.、Citius Pharmaceuticals, Inc.涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Chemomab Therapeutics Ltd较为活跃，换手率分别为216.00%、203.69%、66.10%，振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Aditxt, Inc.，振幅分别为207.68%、11.48%、11.45%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223250a24bf9d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223250a24bf9d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510863479","title":"Chemomab Therapeutics Ltd盘中异动 急速上涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863479","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510863479?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:32","pubTimestamp":1739197950,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时32分，Chemomab Therapeutics Ltd股票出现异动，股价快速拉升5.05%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体涨幅为0.33%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223230961e0018&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223230961e0018&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CMMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509720403","title":"Chemomab Therapeutics Ltd盘中异动 股价大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509720403","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509720403?lang=zh_cn&edition=full","pubTime":"2025-02-08 02:45","pubTimestamp":1738953957,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日02时45分，Chemomab Therapeutics Ltd股票出现异动，股价大幅下跌5.26%。Chemomab Therapeutics Ltd股票所在的生物技术行业中，整体跌幅为0.70%。Chemomab Therapeutics Ltd公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208024557abc65fe0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208024557abc65fe0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CMMB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chemomab.com;investors.chemomab.com","stockEarnings":[{"period":"1week","weight":-0.048},{"period":"1month","weight":0.3438},{"period":"3month","weight":0.5636},{"period":"6month","weight":0.4098},{"period":"1year","weight":-0.1541},{"period":"ytd","weight":0.5636}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Chemomab Therapeutics Ltd.于2011年11月30日根据以色列国法律注册成立。该公司是一家临床阶段的生物技术公司，专注于为纤维化和炎症性疾病开发创新疗法。其主要候选药物nebokitug是一种靶向CCL24的单克隆抗体，已完成针对原发性硬化性胆管炎的2期试验，并计划进行3期试验。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.036667},{"month":2,"riseRate":0.428571,"avgChangeRate":0.031068},{"month":3,"riseRate":0.375,"avgChangeRate":-0.127449},{"month":4,"riseRate":0.375,"avgChangeRate":-0.038683},{"month":5,"riseRate":0.5,"avgChangeRate":0.073293},{"month":6,"riseRate":0.375,"avgChangeRate":-0.025427},{"month":7,"riseRate":0.125,"avgChangeRate":-0.099703},{"month":8,"riseRate":0.5,"avgChangeRate":0.110395},{"month":9,"riseRate":0.125,"avgChangeRate":-0.127514},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.036203},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.050555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.00827}],"exchange":"NASDAQ","name":"Chemomab Therapeutics Ltd.","nameEN":"Chemomab Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Chemomab Therapeutics Ltd.(CMMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Chemomab Therapeutics Ltd.(CMMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Chemomab Therapeutics Ltd.,CMMB,Chemomab Therapeutics Ltd.股票,Chemomab Therapeutics Ltd.股票老虎,Chemomab Therapeutics Ltd.股票老虎国际,Chemomab Therapeutics Ltd.行情,Chemomab Therapeutics Ltd.股票行情,Chemomab Therapeutics Ltd.股价,Chemomab Therapeutics Ltd.股市,Chemomab Therapeutics Ltd.股票价格,Chemomab Therapeutics Ltd.股票交易,Chemomab Therapeutics Ltd.股票购买,Chemomab Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Chemomab Therapeutics Ltd.(CMMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Chemomab Therapeutics Ltd.(CMMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}